Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.

abstract：:Seventeen patients with malignant mesothelioma were treated in a phase II study with carboplatin, a cisplatin analogue without significant nephrotoxicity or neurotoxicity. The drug was given in a dose of 300-400 mg/m2 by i.v. infusion, repeating at 28-day intervals. One patient achieved a complete clinical and radiolo...

journal_title：Cancer chemotherapy and pharmacology

authors： Mbidde EK,Harland SJ,Calvert AH,Smith IE

更新日期：1986-01-01 00:00:00

abstract：:Mitoxantrone, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride, a new antitumor agent was evaluated in nine cancer patients as part of a phase I trial. In general, the drug was well tolerated. Leukopenia was the dose-limiting toxic effect. Mild to moderate leukopenia...

journal_title：Cancer chemotherapy and pharmacology

authors： Alberts DS,Griffith KS,Goodman GE,Herman TS,Murray E

更新日期：1980-01-01 00:00:00

abstract：PURPOSE:The aims of this dose-escalating phase I study were to determine the maximum tolerable dose (MTD) and recommended dose (RD) of 5-fluorouracil (5-FU), docetaxel, and nedaplatin (UDON) combination therapy for future phase II studies, and to evaluate the safety and efficacy of this regimen in patients with untreat...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueda S,Kawakami H,Nishina S,Sakiyama T,Nonagase Y,Okabe T,Tamura T,Nakagawa K

更新日期：2015-08-01 00:00:00

abstract：:Thirty-five patients with a diagnosis of non-Hodgkin's lymphoma of low histological grade were treated with 2 X 10(6)/m2 of human rDNA alpha 2 IFN-a2 by subcutaneous injection. Treatment was continued until progressive disease was documented or one year of therapy had been given. None of the patients had to stop treat...

journal_title：Cancer chemotherapy and pharmacology

authors： Wagstaff J,Loynds P,Crowther D

更新日期：1986-01-01 00:00:00

abstract：:A major side effect of cisplatin treatment is peripheral neuropathy. In the past few years we have provided evidence that the ACTH4-9 analogue ORG 2766 provides protection against this neuropathy in rats and man. In this study we investigated the development of a cisplatin-induced neuropathy and the protective and the...

journal_title：Cancer chemotherapy and pharmacology

authors： Hamers FP,Pette C,Bravenboer B,Vecht CJ,Neijt JP,Gispen WH

更新日期：1993-01-01 00:00:00

abstract：:cis-Diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA, JM8), an analogue of cisplatin showing reduced toxicity in preclinical studies, was evaluated in 60 patients. Doses were given initially every 3 weeks and escalated from 20 to 520 mg/m2. Following this, doses were given every 4 weeks and escalated from 300...

journal_title：Cancer chemotherapy and pharmacology

authors： Calvert AH,Harland SJ,Newell DR,Siddik ZH,Jones AC,McElwain TJ,Raju S,Wiltshaw E,Smith IE,Baker JM,Peckham MJ,Harrap KR

更新日期：1982-01-01 00:00:00

abstract：:Saturable elimination of 5-FU is exhibited in rats during constant infusions. Over the range of 3-480 mg/m2/h, total-body clearance of 5-FU decreases from 600 ml/min/m2 to less than 90 ml/min/m2. Previously published values for catabolism of 5-FU by rat hepatocytes can be used to simulate the plasma concentrations of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Collins JM

更新日期：1985-01-01 00:00:00

abstract：:The 9L gliosarcoma growing subcutaneously in the hind leg of the Fisher 344 rat contains major areas of severe (< 5 mmHg) hypoxia, making up about 49% of the tumor. Intravenous administration of an ultrapurified polymerized bovine hemoglobin solution (8 ml/kg) along with normal air breathing reduces the percentage of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Teicher BA,Holden SA,Menon K,Hopkins RE,Gawryl MS

更新日期：1993-01-01 00:00:00

abstract：:There is no argument over using epidermal growth factor receptor (EGFR) mutation status to guide the frontline treatment for advanced lung adenocarcinoma (LADC); however, the role of the testing in lung squamous cell carcinoma (LSQC) remains controversial. Currently, the guidelines/consensus statements regarding EGFR ...

journal_title：Cancer chemotherapy and pharmacology

authors： Chiu CH,Chou TY,Chiang CL,Tsai CM

更新日期：2014-10-01 00:00:00

abstract：BACKGROUND AND PURPOSE:The optimal chemotherapeutic protocol for the treatment of esophageal cancer has not yet been established. A dose-escalation study of docetaxel combined with cisplatin and 5-fluorouracil (5-FU) was performed to determine the optimal dose in patients with advanced esophageal squamous cell carcinom...

journal_title：Cancer chemotherapy and pharmacology

authors： Tanaka Y,Yoshida K,Sanada Y,Osada S,Yamaguchi K,Takahashi T

更新日期：2010-11-01 00:00:00

abstract：:In order to determine if any inherent sensitivity differences may exist between VP16-213 and VM26 individual human tumors were grown in vitro and drug sensitivities were determined using the soft agar clonogenic assay method. Only nine of the 34 tumors tested so far showed a differing sensitivity to VP16-213 and VM26 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Issell BF,Tihon C,Curry ME

更新日期：1982-01-01 00:00:00

abstract：:Sandostatin immediate release (IR) is frequently used to treat patients with carcinoid tumors. However, some patients are unable to tolerate the immediate side effects of sandostatin IR leading to discontinuation of the drug. There is no literature available to guide the management of patients' sensitivity/intolerance...

journal_title：Cancer chemotherapy and pharmacology

authors： Vinjamaram S,Iyer R

更新日期：2011-07-01 00:00:00

abstract：:The pharmacokinetics of flavone acetic acid (FAA) after a dose of 4.8 mg/m2 given i.v. over 1 h was investigated in 13 patients with different solid tumors. The mean volume of distribution and clearance were 52 +/- 4 l/m2 and 2.6 +/- 0.2 l/h x m2, respectively. A tumor or metastasis biopsy was obtained from six patien...

journal_title：Cancer chemotherapy and pharmacology

authors： Damia G,Freschi A,Sorio R,Braida A,Caruso G,Quaia M,Monfardini S,D'Incalci M

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:We examined the interaction between cyclophosphamide (CPA) and angiostatin (AS) on the growth of primary Lewis lung carcinoma (LLC) tumors and on the development of LLC pulmonary metastases. We studied the effects of AS and CPA on the stages of angiogenesis employing in vitro assays. METHODS:Primary tumor grow...

journal_title：Cancer chemotherapy and pharmacology

authors： Mauceri HJ,Seetharam S,Beckett MA,Schumm LP,Koons A,Gupta VK,Park JO,Manan A,Lee JY,Montag AG,Kufe DW,Weichselbaum RR

更新日期：2002-11-01 00:00:00

abstract：PURPOSE:To characterize the cellular action mechanism of Debio 0507, we compared the major DNA adducts formed by Debio 0507- and oxaliplatin-treated HCT116 human colon carcinoma cells by a combination of inductively coupled plasma mass spectrometry (ICP-MS) and ultraperformance liquid chromatography mass spectrometry (...

journal_title：Cancer chemotherapy and pharmacology

authors： King CL,Ramachandran S,Chaney SG,Collins L,Swenberg JA,DeKrafft KE,Lin W,Cicurel L,Barbier M

更新日期：2012-03-01 00:00:00

abstract：:To evaluate the value of beta-2-microglobulin as an indicator of acute and long-term cis-platinum-induced nephrotoxicity, 51Cr-EDTA clearance and serum concentration and urinary excretion of beta-2-microglobulin were measured in 18 patients treated with a regimen including cis-platinum. Before treatment all values wer...

journal_title：Cancer chemotherapy and pharmacology

authors： Sørensen PG,Nissen MH,Groth S,Rørth M

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by exploiting mitotic catastro...

journal_title：Cancer chemotherapy and pharmacology

authors： Allendorf DJ,Bordoni RE,Grant SC,Saleh MN,Reddy VB,Jerome ML,Dixon PM,Miley DK,Singh KP,Robert F

更新日期：2015-11-01 00:00:00

abstract：PURPOSE:Platinum-based chemotherapy is the recognized first-line treatment for metastatic nasopharyngeal carcinoma (NPC). However, no standard treatment regimens have been established. This phase II study was designed to evaluate the efficacy and safety of a paclitaxel, cisplatin and 5-FU combination in metastatic and/...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen C,Wang FH,An X,Luo HY,Wang ZQ,Liang Y,Zhang L,Li YH

更新日期：2013-02-01 00:00:00

abstract：BACKGROUND:No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors. PATIENTS AND METHODS:We investigated in patients with T2-T3 N0-3 ER, PgR <10% and HER2 negative breast cancers the activity both in ter...

journal_title：Cancer chemotherapy and pharmacology

authors： Torrisi R,Balduzzi A,Ghisini R,Rocca A,Bottiglieri L,Giovanardi F,Veronesi P,Luini A,Orlando L,Viale G,Goldhirsch A,Colleoni M

更新日期：2008-09-01 00:00:00

abstract：:We compared the safety and efficacy in mice with peritoneal carcinomatosis of two etoposide formulations: an aqueous solution (Etp-sol) and particles suspended in oil (the addition products of iodine and the ethyl esters of the fatty acids obtained from poppy-seed oil (Lipiodol) or sesame oil; Etp-oil). We also invest...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee JS,Takahashi T,Hagiwara A,Yoneyama C,Itoh M,Sasabe T,Muranishi S,Tashima S

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:Since the hypothesis that solid tumors cause angiogenesis by secreting pro-angiogenic factors was introduced, research on angiogenesis has proceeded continuously. Development of inhibitors targeting the angiogenic tyrosine kinases, to block downstream signal transduction pathways, has become an important approa...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang J,Zhang L,Wang Y,Zhao G

更新日期：2016-05-01 00:00:00

abstract：:The effect of selenite coadministration on the toxicity and antitumor activity of repeated treatment with high doses of cis-diamminedichloroplatinum (cis-DDP) was examined in mice. Sodium selenite was injected s.c. into separate abdominal sites of mice together with cis-DDP at a molar ratio of 1:3.5 (selenite to cis-D...

journal_title：Cancer chemotherapy and pharmacology

authors： Satoh M,Naganuma A,Imura N

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:The chimeric BR96-doxorubicin (DOX) immunoconjugate, BMS 182248, has induced remissions and cures of human lung adenocarcinoma (L2987) implanted in athymic mice. The purpose of this study was to evaluate the biodistribution of DOX after BMS 182248 administration to tumor-bearing mice and to evaluate the ability...

journal_title：Cancer chemotherapy and pharmacology

authors： Mosure KW,Henderson AJ,Klunk LJ,Knipe JO

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:Low-dose methotrexate (MTX) therapy is the cornerstone treatment of acute lymphoblastic leukemia (ALL) and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides (6-TGN). Yet, data have established that high-dose MTX (HDMTX) hampers the accumulation of 6-TGN in red blood cells (RBC) ...

journal_title：Cancer chemotherapy and pharmacology

authors： Adam de Beaumais T,Dervieux T,Fakhoury M,Medard Y,Azougagh S,Zhang D,Yakouben K,Jacqz-Aigrain E

更新日期：2010-09-01 00:00:00

abstract：PURPOSE:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are key drugs in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR activating mutations. We assessed the efficacy and safety of one EGFR tyrosine kinase inhibitor, erlotinib, in elderly Japanese patients with EGFR-mutated NSCLC....

journal_title：Cancer chemotherapy and pharmacology

authors： Inoue Y,Inui N,Asada K,Karayama M,Matsuda H,Yokomura K,Koshimizu N,Imokawa S,Yamada T,Shirai T,Kasamatsu N,Suda T

更新日期：2015-07-01 00:00:00

abstract：:Trastuzumab has deeply and radically changed the course of HER2-positive breast cancer disease. The recent development of a subcutaneous (SC) formulation of trastuzumab is an important step towards improved patients' care. SC trastuzumab at a fixed dose of 600 mg administered every 3 weeks for about 5 min provides a v...

journal_title：Cancer chemotherapy and pharmacology

authors： Launay-Vacher V

更新日期：2013-12-01 00:00:00

abstract：:PANC02 is a unique experimental animal tumor that fails to respond significantly to any known clinically active antitumor agent. In this regard, the murine ductal adenocarcinoma resembles its human counterpart. To study the mechanism for its intrinsic resistance to 6-thioguanine (TG), we compared the metabolism of the...

journal_title：Cancer chemotherapy and pharmacology

authors： Pan BF,Priebe TS,Nelson JA

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Imatinib mesylate (Imatinib), clinically employed for chronic myeloid leukemia and gastrointestinal stromal tumors, is a selective inhibitor of the tyrosine kinases, c-abl, c-kit and PDGFRs. Due to the frequent expression of these genes in breast cancer cells, the clinical efficacy of Imatinib has recently been...

journal_title：Cancer chemotherapy and pharmacology

authors： Rappa G,Anzanello F,Lorico A

更新日期：2011-04-01 00:00:00

abstract：:Use of cross-sectional imaging to identify whole-body lean soft-tissue mass has recently emerged as an attractive prognostic factor for chemotherapy toxicities. Beyond that, there is increasing interest in use of lean soft-tissue mass as a more accurate method for dosing chemotherapy, as compared to body surface area....

journal_title：Cancer chemotherapy and pharmacology

authors： Hopkins JJ,Sawyer MB

更新日期：2018-07-01 00:00:00

abstract：:The toxic effect of 3'-deoxyadenosine N1-oxide (3'-dANO) on mice, on their different organs, and on Ehrlich ascites tumor cells was studied. In both healthy and tumour-bearing animals, the lethal dose for 10% of the mice receiving i.p. injections (LD10) of 3'-dANO was estimated to be about 300 mg/kg x 4 days in one mo...

journal_title：Cancer chemotherapy and pharmacology

authors： Svendsen KR,Overgaard-Hansen K,Frederiksen S,Engelholm SA,Pedersen NT,Vindeløv LL

更新日期：1992-01-01 00:00:00